Results 211 to 220 of about 604,654 (341)

Attitudes towards supervised consumption sites and e-health overdose response interventions: development and reliability of the Canadian National Questionnaire on Overdose Monitoring (CNQOM). [PDF]

BMJ Open
Rider N, Seo B, Viste D, Rioux W, Sedaghat N, Pan B, Al Hamarneh YN, McCormack GR, Aghajafari F, McDougall L, Ghosh SM.   +10 more
europepmc   +1 more source

Araneae of Alberta and Saskatchewan, Canada

, 2001
Donald J. Buckle, Robert G. Holmberg
openalex   +1 more source

Inroads into epilepsy through high‐frequency oscillations: Achievements and benchmark areas for improvement

Epilepsia, EarlyView.
Abstract High‐frequency oscillations (HFOs) were discovered more than 20 years ago, and since then they have been studied intensively in the context of epilepsy. HFOs encompass a broad spectrum of oscillations, typically ranging from 80 Hz to several kHz, that include both normal and pathological oscillations, documented in people with epilepsy and ...
Christos Panagiotis Lisgaras, Birgit Frauscher, Jean Gotman, Julia Jacobs, Philippe Kahane, Richard J. Staba, Maeike Zijlmans   +6 more
wiley   +1 more source

La circolazione del libro nella Parma dei Borbone: l’avvio di una ricerca

TECA, 2011
Alberta Pettoello
doaj   +1 more source

The investigation and prevalence of pulmonary embolism among emergency department patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD): A multi-centered linked administrative database study. [PDF]

PLoS One
Rowe BH, Yang EH, Villa-Roel C, Zheng B, Mayers I.   +4 more
europepmc   +1 more source

Some Aspects of Regeneration Silviculture in Spruce-Aspen Stands in Alberta

, 1959
L. A. Smithers
openalex   +1 more source

Ketogenic diet for infantile epileptic spasms

Epilepsia Open, EarlyView.
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury, Anamika Choudhary, Andy Cheuk‐Him Ng, Cezar Gavrilovici   +3 more
wiley   +1 more source

Variation in Variation Measurement: A Mapping Review of Methods to Study Clinical Variation. [PDF]

J Eval Clin Pract
Quinn AE, Black JE, Chew D, Williamson TS, Yergens D, Faris P, Au F, Fletcher JM, Sidhu S, Drummond R, Skidmore B, Manns B.   +11 more
europepmc   +1 more source

Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study (ELUCID)

Epilepsia Open, EarlyView.
Abstract Objective Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure.
Alice D. Lam, Emily L. Johnson, Rani A. Sarkis, Leah J. Blank, Tyler E. Gaston, Mouhsin M. Shafi, Rodrigo Zepeda, Kyle R. Pellerin, Nathalie Jette, Douglas N. Greve, Lori B. Chibnik, Rebecca E. Amariglio, Gad A. Marshall, M. Brandon Westover   +13 more
wiley   +1 more source

Influence of the COVID-19 pandemic on drug and healthcare utilisation among First Nations with diabetes in Alberta, Canada: a retrospective cohort study. [PDF]

BMJ Open
Weaver O, Sarin C, Samanani S, Crowshoe L, Ye M, Eurich DT.   +5 more
europepmc   +1 more source